“Adjuvanted Intranasal Norwalk Virus-Like Particle Vaccine Elicits Antibodies and Antibody-Secreting Cells That Express Homing Receptors for Mucosal and Peripheral Lymphoid Tissues”, J Infect Dis, vol. 202, pp. 1648-1658, 2010.,
“Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers”, J Infec Dis, vol. 183, pp. 1343-52, 2001.
“Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine”, J Infect Dis, vol. 212, no. 4, pp. 525-530, 2015.,
“Safety and Immunogenicity of HCV E1E2 Vaccine Adjuvanted with MF59 Administered to Healthy Adults”, Vaccine, vol. 28, pp. 6367-6373, 2010.,